BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16292351)

  • 1. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.
    Le LP; Rivera AA; Glasgow JN; Ternovoi VV; Wu H; Wang M; Smith BF; Siegal GP; Curiel DT
    Gene Ther; 2006 Mar; 13(5):389-99. PubMed ID: 16292351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
    Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
    Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenoviral therapy in gallbladder carcinoma.
    Tekant Y; Davydova J; Ramirez PJ; Curiel DT; Vickers SM; Yamamoto M
    Surgery; 2005 May; 137(5):527-35. PubMed ID: 15855925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
    Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
    J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
    Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
    Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
    Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
    J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
    Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
    Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
    Graat HC; Witlox MA; Schagen FH; Kaspers GJ; Helder MN; Bras J; Schaap GR; Gerritsen WR; Wuisman PI; van Beusechem VW
    Br J Cancer; 2006 Jun; 94(12):1837-44. PubMed ID: 16736005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model.
    Nagayama Y; Nakao K; Mizuguchi H; Hayakawa T; Niwa M
    Gene Ther; 2003 Aug; 10(16):1400-3. PubMed ID: 12883537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
    Hoffmann D; Meyer B; Wildner O
    J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.